Top Markets
#1 Cysic Cysic +7.96%
#2 Palladium Network Palladium Network +6.82%
#3 Pieverse Pieverse +3.88%
#4 Akedo Akedo +2.15%
#5 Bless Bless +1.27%
#6 aPriori aPriori +1.17%
#7 Prom Prom +1.16%
#8 Zest Protocol Zest Protocol +1.01%
#9 Test Test +0.95%
#10 Open Campus Open Campus +0.84%
Coin of the day
Cysic Cysic
Settings
Language
ENGLISH
Currency
USD
Theme
Brickell Biotech, Inc. Brickell Biotech, Inc.

Brickell Biotech, Inc.

BBI
Rank in Stocks #40377
Brickell Biotech, Inc. is a pharmaceutical company currently in the clinical... Brickell Biotech, Inc. is a pharmaceutical company currently in the clinical development phase, dedicated to creating prescription medicines for various debilitating conditions, including autoimmune and inflammatory disorders, primarily within the United States. Its product pipeline includes sofpironium bromide, which has successfully finished Phase III clinical trials for treating excessive underarm sweating (primary axillary hyperhidrosis). Other notable candidates are BBI-02, an oral DYRK1A inhibitor targeting autoimmune and inflammatory diseases, and BBI-10, a covalent stimulator of interferon genes (STING) inhibitor, being explored for autoinflammatory and rare genetic illnesses. The company is also advancing next-generation kinase inhibitors. Brickell Biotech collaborates with several partners, such as Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. Established in 2009, its main office is located in Boulder, Colorado.
Share Price
$2.35
Last synced: 2022-09-07
Market Cap
$162.94K
Change (1 day)
2.17%
Change (1 year)
0.00%
Country
US
Trade Brickell Biotech, Inc. (BBI)

Category

Healthcare
P/E ratio for Brickell Biotech, Inc. (BBI)
P/E ratio as of 2026 TTM: 0
According to Brickell Biotech, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Brickell Biotech, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.